Recent developments in treatment of latent tuberculosis infection

Indian Journal of Medical Research

Volumn 133, Issue 3, 2011, Pages 257-266

  Menzies, Dick ^a   Al Jahdali, Hamdan ^a   Al Otaibi, Badriah ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Latent tuberculosis; Tuberculosis; Tuberculosis infection; Tuberculosis prevention; Tuberculosis treatment

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER TOXICITY; NONHUMAN; PATIENT EDUCATION; PATIENT MONITORING; REVIEW; RISK REDUCTION; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS; DRUG COMBINATION;

ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; TUBERCULOSIS;

EID: 79952967246     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. World Health Organization. Global tuberculosis control. Surveillance, planning, financing: 2010. (Report No.: WHO/HTM/TB/2006.362). Geneva: World Health Organization; 2010.
2. Rieder HL. Epidemiologic basis of tuberculosis control. 1st ed. Paris, France; International Union Against Tuberculosis and Lung Disease; 1999. p 1-162.
3. Enarson DA, Rieder HL, Arnadottir T, Trebucq A. Tuberculosis guide for low income countries. 5th ed. Paris: International Union Against Tuberculosis and Lung Disease; 2000.
4. Rieder HL. Interventions for tuberculosis control and elimination. Paris international Union Against Tuberculosis and Lung Disease; 2002.
5. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969; 17: 28-106.
6. Sumartojo E. When tuberculosis treatment fails: a social behavioural account of patient adherence. Am Rev Resp Dis 1993; 147: 1311-20.
7. Dosanjh DPS, Hinks T, Innes JA, Deeks JJ, Pasvol G, Hackforth S, et al. Improved diagnostic evaluation of suspected tuberculosis in routine practice. Ann Int Med 2008; 148: 325-33.
8. Dash LA, Comstock GW, Flynn JPG. Isoniazid preventive therapy. Am Rev Respir Dis 1980;121:1039-44.
9. Miller B, Snider DE. Physician noncompliance with tuberculosis preventive measures. Am Rev Resp Dis 1987; 135: 1-2.
10. Sorresso D, Mehta JB, Harvill LM, Bentley S. Underutilization of isoniazid chemoprophylaxis in tuberculosis contacts 50 years of age and older: a prospective study. Chest 1995; 108: 706-11.
11. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; 2: CD001363.
12. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health org 1982; 60: 555-64.
13. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-47.
14. Long RL, Ellis E. Canadian tuberculosis standards, 6th ed. Toronto: Canadian Lung Association, Public Health Agency of Canada, Tuberculosis Prevention and Control; 2007.
15. Snider DE Jr., Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255: 1579-83.
16. Dasgupta K, Schwartzman K, Marchand R, Tannenbaum TN, Brassard P, Menzies D. Comparison of cost effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000; 162: 2079-86.
17. Comstock GM. How much isoniazid is needed for prevention of tuberculosis in immunocompetent adults. Int J Tuberc Lung Dis 1999; 3: 847-50.
18. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis Infection in a Public Health Clinic. Am J Respir Crit Care Med 2003; 168: 443-7.
19. Jasmer RM, Snyder DC, Chin DP, Hopewell PC, Cuthbert SS, Paz EA, et al. Twelve months of isoniazid compared with four months of Isoniazid and Rifampin for persons with radiographic evidence of previous tuberculosis. Am J Respir Crit Care Med 2000; 162: 1648-52.
20. Dutt AK, Stead WW. Tuberculosis in the elderly. In: Bass JB, editor. The medical clinics in North America. Montreal: WB Saunders and CO.; 1993. p. 1353-68.
21. American Thoracic Society, Center for Disease Control. Preventive treatment of Tuberculosis. A joint statement of the Amercian Thoracic Society, National Tuberculosis and Respiratory Disease Association, and the Centre for Disease Control. Am Rev Respir Dis 1971; 104: 460-3.
22. Garibaldi RA, Drustin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Am Rev Respir Dis 1972; 106: 357-65.
23. Kopanoff DE, Snider D, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis 1978; 117: 991-1001.
24. Snider D, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992; 145: 494-7.
25. Salpeter SR. Fatal Isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159: 560-4.
26. Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventative therapy of tuberculosis with Rifampin and Pyrazinamide. Am Rev Respir Dis 1989; 140: 1189-93.
27. Gao XF, Wang L, Liu GJ, Wen J, Sun X, Xie Y, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 2006; 10: 1080-90.
28. Center for Disease Control. Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection - New York and Georgia, 2000. Morb Mortal Wkly Rep 2001; 50: 289-91.
29. American Thoracic Society, Centres for Disease Control. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in the American Thoracic Society/ CDC recommendations. MMWR 2001; 50: 733-5.
30. Hong Kong Chest Service Tuberculosis Research Centre MBMRC. A Double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
31. Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166: 1863-70.
32. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130: 1712.
33. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-9.
34. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al-Jahdali H, et al. Adverse events with 4 months rifampin or 9 months isoniazid as therapy for latent TB infection: results of a randomized trial. Ann Intern Med 2008; 149: 689-97.
35. Omerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998; 78: 169-71.
36. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40: 670-6.
37. Kunst H, Khan KS. Age-related risk of hepatotoxicity in treatment of latent tuberculosis infection; a systematic review. Int J Tuberc Lung Dis 2010; 14: 1374-81.
38. Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. A Randomized, Placebo- Controlled Trial of 6 versus 36 Months Isonizid tuberculosis Preventive Therapy for HIV-infected Adults in Botswana. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco 2010, poster #104LB 2010 February 18.
39. Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis 1986; 133: 431-6.
40. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventative therapy with Pyrazinamide and Ofloxacin. Clin Infect Dis 1997; 24: 1264-5.
41. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005; 26: 462-4.
42. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatic N, Bozeman L, et al. Substitution of Moxifloxacin for Isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-80.
43. Adhikari N, Menzies R. Community-based tuberculin screening in Montreal: A cost-outcome description. Am J Public Health 1995; 85: 786-90.
44. Rose DN, Schechter CB, Silver AL. The age threshold for isoniazid chemoprophylaxis: a decision analysis for low risk tuberculin reactors. JAMA 1986; 256: 2709-13.
45. Tsevat J, Taylor WC, Wong JB, Pauker SG. Isoniazid for tuberculin reactor: take it or leave it. Am Rev Resp Dis 1988; 137: 215-20.
46. Colice GL. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors. Arch Intern Med 1990; 150: 2517-22.
47. Jordan TJ, Lewit EM, Reichman LB. Isoniazid preventive therapy for tuberculosis. Decision analysis considering ethnicity and gender. Am Rev Respir Dis 1991; 144: 1118-9.
48. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored Isoniazid Prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127: 1051-61.
49. Jordan TJ, Lewit EM, Montgomery RL, Reichman LB. Isoniazid as preventive in HIV-infected intravenous drug abusers. A decision analysis. JAMA 1991; 265: 2987-91.
50. Rose DN. Short-course prophylaxis against tuberculosis in HIV-infected persons- a decisions and cost-effectiveness analysis. Ann Intern Med 1998; 129: 779-86.
51. Menzies D, Gardiner G, Farhat M, Greenway C, Pai M. Thinking in three dimensions: a web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 2008; 12: 498-505.
52. BC Center for Disease Control. Annual Report Tuberculosis Control in 2002. Vancouver, BC Ministry of Health; 2003.
53. Blum RN, Polish LB, Tapy JM, Catlin BJ, Cohn DL. Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status. Chest 1993; 103: 1670-4.
54. Yuan L, Richardson E, Kendall PRW. Evaluation of a tuberculosis screening program for high-risk students in Toronto schools. CMAJ 1995; 153: 925-32.
55. Onofre Moran-Mendoza A. The value of the tuberculin skin test size in predicting the development of tuberculosis in contacts of active cases Department of Health Care and Epidemiology, University of British Columbia; 2004.
56. Jereb J, Etkind SC, Joglar OT, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003; 7: S384-90.
57. Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, et al. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. U S National Library of Medicine, National Institute of Health, 1995; March 9, p. 267-73.
58. World Health Organization. Guidelines for intensified tuberculosis case finding and isoniazid preventtive therapy for people living with HIV in resource constrained settings. Geneva: World Health Organization, 2011.
59. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-72.
60. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337: 801-8.
61. Hawken MP, Meme HK, Chakaya JM, Elliott LC, Morris JS, Githui, et al. Isoniazid preventive therapy for tuberculosis in HIV-infected adults: results of a randomized controlled trial. AIDS 1997; 11: 875-82.
62. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-57.
63. Gordin FM, Chaisson RE, Matts JP, Valdespino JL, Coberly J, Miller C, De lourdes Carcia M, et al. Rifampin and Pyrazinamide vs Isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 2000; 283: 1445-50.
64. Garcia ML, Valdespino JL, Garcia-Sancho C, Weissenbacher M, Daniels E, Peruga A, et al. Compliance and side effects to chemoprophylaxis for TB in HIV+. Mexican experience. IX International Conference on AIDS, Abstract-Po-BO7-11. 1993.
65. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. The Cochrane Library 1. 2010.
66. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Mwansa J, Menzies D, et al. Predictive value of interferon release assays for incident active tuberculoasis: A systematic review. PLoS one in Press 2010.
67. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159: 15-21.
68. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.
69. Menzies D, Adhikari N, Arieta M, Loo V. Efficacy of environmental measures in reducing potentially infectious bioaerosols during sputum induction. Infect Control Hosp Epidemiol 2003; 24: 483-9.
70. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137: 640-7.
71. Haley CA, Stephan S, Vossel LF, Sherfy E.A., Laserson KF, Kainer MA. Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection. Int J Tuberc Lung Dis 2008: 12: 160-7.